Maximally tolerated versus minimally effective dose: The case of rituximab in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 3, 2012, Pages 377-378

  Nielsen, A Scott ^a   Miravalle, Augusto ^b   Langer Gould, Annette ^c   Cooper, Joanna ^d   Edwards, Keith R ^e   Kinkel, R Philip ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

^d East Bay Physicians Medical Group   (United States)

^e Multiple Sclerosis Center of NE New York ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB; RITUXIMAB;

DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LETTER; LOW DRUG DOSE; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; THRUSH; URINARY TRACT INFECTION;

EID: 84857856422     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511418631     Document Type: Letter

References (7)

1. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688 (Pubitemid 351240747)
2. Roll P, Arumugam P, Kneitz C, Dorner T, Hans-Peter T. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006 ; 54: 2377-2386 (Pubitemid 44204997)
3. Carson K, Evens A, Richey E, Habermann T, Focosi D, Seymour J, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood. 2009 ; 14: 4834-4840
4. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient withrheumatoid arthritis. Arthritis Rheum. 2009 ; 60: 3225-3228
5. Clifford D, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011 ;:
6. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol. 2008 ; 63: 395-400 (Pubitemid 351499869)
7. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH). Guideline for industry: Dose-response information to support drug registration. Federal Register1994; 59:55972-55976. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm073115.pdf.